Sentiment-Signal
Score-Verlauf (90 Tage)
Stammdaten
Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III clinical trial for the treatment of acromegaly, as well as completed phase II clinical trial to treat carcinoid syndrome and nonfunctional neuroendocrine tumors (NETs). The company is also developing CRN04777, an oral selective nonpeptide somatostatin type 5 receptor agonist, which is in phase I clinical trial for the treatment of congenital hyperinsulinism; and CRN04894, an oral adrenocorticotrophic hormone antagonist that is in phase I clinical trial for the treatment of Cushing's and congenital adrenal hyperplasia diseases. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
Unternehmen & Branche
| Name | Crinetics Pharmaceuticals, Inc. |
|---|---|
| Ticker | CRNX |
| CIK | 0001658247 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2834 · Pharmaceutical Preparations |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 3,96 Mrd. USD |
| Beta | 0,31 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | 7,696,000 | -465,317,000 | -4.95 | 1,126,257,000 | 992,083,000 |
| 2025-09-30 | 10-Q | 143,000 | -130,091,000 | -1.38 | 1,196,031,000 | 1,072,169,000 |
| 2025-06-30 | 10-Q | 1,031,000 | -115,637,000 | -1.23 | 1,289,574,000 | 1,171,526,000 |
| 2025-03-31 | 10-Q | 361,000 | -96,774,000 | -1.04 | 1,361,327,000 | 1,254,000,000 |
| 2024-12-31 | 10-K | 1,039,000 | -298,408,000 | -3.69 | 1,434,592,000 | 1,324,805,000 |
| 2024-09-30 | 10-Q | 0 | -76,828,000 | -0.96 | 937,374,000 | 832,980,000 |
| 2024-06-30 | 10-Q | 399,000 | -74,055,000 | -0.94 | 935,535,000 | 830,763,000 |
| 2024-03-31 | 10-Q | 640,000 | -66,930,000 | -0.93 | 978,153,000 | 874,933,000 |
| 2023-12-31 | 10-K | 4,013,000 | -214,529,000 | -3.69 | 635,353,000 | 539,106,000 |
| 2023-09-30 | 10-Q | 346,000 | -57,458,000 | -1.01 | 641,537,000 | 547,748,000 |
| 2023-06-30 | 10-Q | 988,000 | -50,979,000 | -0.94 | 293,254,000 | 254,116,000 |
| 2023-03-31 | 10-Q | 2,679,000 | -45,995,000 | -0.85 | 314,009,000 | 280,330,000 |
| 2022-12-31 | 10-K | 4,737,000 | -163,918,000 | -3.15 | 352,176,000 | 316,328,000 |
| 2022-09-30 | 10-Q | 458,000 | -41,925,000 | -0.78 | 384,880,000 | 351,372,000 |
| 2022-06-30 | 10-Q | 439,000 | -42,375,000 | -0.81 | 421,733,000 | 386,165,000 |
| 2022-03-31 | 10-Q | 3,131,000 | -34,627,000 | -0.73 | 333,286,000 | 303,044,000 |
| 2021-12-31 | 10-K | 1,078,000 | -107,641,000 | -2.80 | 351,015,000 | 331,944,000 |
| 2021-09-30 | 10-Q | 0 | -27,851,000 | -0.73 | 209,359,000 | 193,590,000 |
| 2021-06-30 | 10-Q | -26,095,000 | -0.70 | 216,929,000 | 201,440,000 | |
| 2021-03-31 | 10-Q | 0 | -22,901,000 | 163,550,000 | 149,480,000 |
Fondsaktivität (Vorquartalsvergleich)
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-04-08 | Knight Jeff E. | Officer, Chief Dev. & Operating Officer | Open Market Sale | -85,163 | 40.10 | -3,415,036.30 | -658,9% | |
| 2026-03-16 | Knight Jeff E. | Officer, Chief Operating Officer | Open Market Sale | -5,950 | 37.11 | -220,804.50 | -42,6% | |
| 2026-03-16 | Knight Jeff E. | Officer, Chief Operating Officer | Open Market Sale | -3,961 | 37.77 | -149,606.97 | -28,9% | |
| 2026-03-12 | Vivaldi Coelho Rogerio | Director | Open Market Sale | -4,477 | 36.08 | -161,530.16 | -31,2% | |
| 2026-03-12 | Vivaldi Coelho Rogerio | Director | Open Market Sale | -523 | 36.77 | -19,230.71 | -3,7% | |
| 2026-03-03 | Schilke Tobin | Officer, Chief Financial Officer | Open Market Sale | -6,713 | 39.67 | -266,304.71 | -51,4% | |
| 2026-01-05 | Kalofonos Isabel | Officer, Chief Commercial Officer | Open Market Sale | -2,500 | 55.00 | -137,500.00 | -26,5% | |
| 2025-10-01 | Pizzuti Dana | Officer, Chief Med and Dev Officer | Open Market Sale | -5,000 | 41.81 | -209,050.00 | -40,3% | |
| 2025-09-26 | Fust Matthew K | Director | Open Market Sale | -16,000 | 44.75 | -716,000.00 | -138,1% | |
| 2025-09-26 | Struthers Richard Scott | Director, Officer, President & CEO | Open Market Sale | -4,000 | 45.00 | -180,000.00 | -34,7% | |
| 2025-09-02 | Pizzuti Dana | Officer, Chief Med and Dev Officer | Open Market Sale | -5,000 | 32.10 | -160,500.00 | -31,0% | |
| 2025-08-22 | Pizzuti Dana | Officer, Chief Med and Dev Officer | Open Market Sale | -30,000 | 30.43 | -912,900.00 | -176,1% | |
| 2025-08-20 | Pizzuti Dana | Officer, Chief Med and Dev Officer | Open Market Sale | -6,492 | 29.18 | -189,436.56 | -36,5% |
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.